Group sequential designs for clinical trials with bivariate endpoints
From MaRDI portal
Publication:6629838
DOI10.1002/SIM.8696zbMATH Open1546.62337MaRDI QIDQ6629838
John M. Kittelson, Neil A. Goldenberg, Patrick J. Blatchford, Junxiao Hu
Publication date: 30 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Symmetric Group Sequential Test Designs
- Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Coupled Error Spending Functions for Parallel Bivariate Sequential Tests
- Group-Sequential Analysis Incorporating Covariate Information
- An Adaptive Approach to Implementing Bivariate Group Sequential Clinical Trial Designs
- Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
- A Unifying Family of Group Sequential Test Designs
- Bivariate Sequential Designs for Phase II Trials
- Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints
This page was built for publication: Group sequential designs for clinical trials with bivariate endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6629838)
